These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Body and blood clearance and marrow radiation dose of 131I-Lym-1 in patients with B-cell malignancies. DeNardo GL; Mahe MA; DeNardo SJ; Macey DJ; Mirick GR; Erwin WD; Groch MW Nucl Med Commun; 1993 Jul; 14(7):587-95. PubMed ID: 8355919 [TBL] [Abstract][Full Text] [Related]
12. Estimation of radiation absorbed doses to the red marrow in radioimmunotherapy. Macey DJ; DeNardo SJ; DeNardo GL; DeNardo DA; Shen S Clin Nucl Med; 1995 Feb; 20(2):117-25. PubMed ID: 7720301 [TBL] [Abstract][Full Text] [Related]
13. Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. DeNardo GL; DeNardo SJ; Goldstein DS; Kroger LA; Lamborn KR; Levy NB; McGahan JP; Salako Q; Shen S; Lewis JP J Clin Oncol; 1998 Oct; 16(10):3246-56. PubMed ID: 9779698 [TBL] [Abstract][Full Text] [Related]
14. Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study. Denardo GL; Denardo SJ; Kukis DL; O'Donnell RT; Shen S; Goldstein DS; Kroger LA; Salako Q; Denardo DA; Mirick GR; Mausner LF; Srivastava SC; Meares CF Anticancer Res; 1998; 18(4B):2779-88. PubMed ID: 9713461 [TBL] [Abstract][Full Text] [Related]
15. Application of the linear-quadratic model to myelotoxicity associated with radioimmunotherapy. Wilder RB; DeNardo GL; Sheri S; Fowler JF; Wessels BW; DeNardo SJ Eur J Nucl Med; 1996 Aug; 23(8):953-7. PubMed ID: 8753685 [TBL] [Abstract][Full Text] [Related]